Professor Lee Seung-soon of Hallym University Chuncheon Sacred Heart Hospital, Korean Infectious Society and Korean Antibacterial ResearchLaw Society Award for Best Performance
Nov 21, 2024
Lee Seung-soon, Professor of Infectious Diseases at Hallym University Chuncheon Sacred Heart Hospital, held from the 7th to the 8th at Rahane Select Gyeongju, Gyeongju, Gyeongsangbuk-do, 2024 Korean Society of Infectious Diseases and Korean AntibioticsHe won the best performance award at the Law Society Autumn Conference.
Korean Infectious Society and Korean Antibacterial SocietyThe Law Association selects the winners of the Excellence Festival Award after strict screening by the academic committee and the judging committee for the abstract published at the Korean Infectious Society's Autumn Conference in the current year.
Professor Lee Seung-soon was honored with a study on the effectiveness and safety of colistin-based combination therapy and high-dose ampicillin-sulfactam-based combination therapy in nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii: CRAB.
This study was conducted as a retrospective cohort study that selected 84 patients who received colistin-based combination therapy between June 2021 and May 2022 and 95 patients with pneumonia caused by CRAB strains who received high-dose ampicillin- and sulfactam-based combination therapy between October 2022 and September 2023.
The research team suggested that high-dose ampicillin- and sulbactam-based combination therapy is a better and safer treatment than colistin-based combination therapy in nosocomial pneumonia caused by CRAB strains. On the 28th day after the start of treatment, the mortality rate was significantly lower in the high-dose ampicillin and sulbactam groups, 20% in the high-dose ampicillin and sulbactam groups and 61% in the colistin groups. In addition, the success rate of clinical treatment on the 14th and 28th days of treatment was significantly higher in the high-dose ampicillin and sulbactam groups than in the colistin group, and the renal injury on the 28th day of treatment was significantly lower in the high-dose ampicillin and sulbactam groups.
Professor Lee Seung-soon said, `Despite the high mortality rate of CRAB strain infection, the introduction of new antibiotics in Korea has been delayed, and even high-dose ampicillin and sulbactam according to the treatment guidelines of advanced Western countries have not been able to respond quickly to changes in treatment guidelines, such as reducing insurance benefits according to the past approval standards of the Ministry of Food and Drug Safety. Various domestic research results, including this study, as well as the Korean Infectious Society and the Korean Antibacterial SocietyWe look forward to improving the prognosis of treatment for antibiotic-resistant bacterial infections through active responses from the legal council. "
Korean Infectious Society and Korean Antibacterial SocietyThe Law Association selects the winners of the Excellence Festival Award after strict screening by the academic committee and the judging committee for the abstract published at the Korean Infectious Society's Autumn Conference in the current year.
Professor Lee Seung-soon was honored with a study on the effectiveness and safety of colistin-based combination therapy and high-dose ampicillin-sulfactam-based combination therapy in nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii: CRAB.
This study was conducted as a retrospective cohort study that selected 84 patients who received colistin-based combination therapy between June 2021 and May 2022 and 95 patients with pneumonia caused by CRAB strains who received high-dose ampicillin- and sulfactam-based combination therapy between October 2022 and September 2023.
The research team suggested that high-dose ampicillin- and sulbactam-based combination therapy is a better and safer treatment than colistin-based combination therapy in nosocomial pneumonia caused by CRAB strains. On the 28th day after the start of treatment, the mortality rate was significantly lower in the high-dose ampicillin and sulbactam groups, 20% in the high-dose ampicillin and sulbactam groups and 61% in the colistin groups. In addition, the success rate of clinical treatment on the 14th and 28th days of treatment was significantly higher in the high-dose ampicillin and sulbactam groups than in the colistin group, and the renal injury on the 28th day of treatment was significantly lower in the high-dose ampicillin and sulbactam groups.
Professor Lee Seung-soon said, `Despite the high mortality rate of CRAB strain infection, the introduction of new antibiotics in Korea has been delayed, and even high-dose ampicillin and sulbactam according to the treatment guidelines of advanced Western countries have not been able to respond quickly to changes in treatment guidelines, such as reducing insurance benefits according to the past approval standards of the Ministry of Food and Drug Safety. Various domestic research results, including this study, as well as the Korean Infectious Society and the Korean Antibacterial SocietyWe look forward to improving the prognosis of treatment for antibiotic-resistant bacterial infections through active responses from the legal council. "
|
bellho@sportschosun.com
